Rare adverse events in clinical trials: understanding the rule of three

  Investigators should report rare and very rare adverse events in clinical trials: Igho Onakpoya reports why it is important that all events are reported irrespective of their frequency.   Even though they may not give a signal in any single trial, a meta-analysis could reveal potentially important drug-adverse event associations that might require further […]

Read More…